AbbVie Inc. $ABBV Shares Bought by Wellspring Financial Advisors LLC

Wellspring Financial Advisors LLC lifted its holdings in AbbVie Inc. (NYSE:ABBV) by 140.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,748 shares of the company’s stock after purchasing an additional 6,281 shares during the period. Wellspring Financial Advisors LLC’s holdings in AbbVie were worth $2,457,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. RM Financial Services LLC acquired a new stake in shares of AbbVie during the 4th quarter valued at $217,000. J.Safra Asset Management Corp lifted its position in shares of AbbVie by 12.6% during the 4th quarter. J.Safra Asset Management Corp now owns 6,227 shares of the company’s stock valued at $1,423,000 after acquiring an additional 697 shares during the last quarter. GWN Securities Inc. lifted its position in shares of AbbVie by 22.5% during the 4th quarter. GWN Securities Inc. now owns 6,343 shares of the company’s stock valued at $1,450,000 after acquiring an additional 1,165 shares during the last quarter. Janney Montgomery Scott LLC lifted its position in shares of AbbVie by 12.8% during the 4th quarter. Janney Montgomery Scott LLC now owns 1,082,861 shares of the company’s stock valued at $247,423,000 after acquiring an additional 122,703 shares during the last quarter. Finally, First American Trust FSB lifted its position in shares of AbbVie by 5.8% during the 4th quarter. First American Trust FSB now owns 62,209 shares of the company’s stock valued at $14,214,000 after acquiring an additional 3,413 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Performance

ABBV stock opened at $225.16 on Thursday. The stock has a market cap of $397.82 billion, a P/E ratio of 110.92, a P/E/G ratio of 0.69 and a beta of 0.32. The firm has a 50 day simple moving average of $210.64 and a 200 day simple moving average of $219.09. AbbVie Inc. has a 52 week low of $181.73 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. The business had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same period last year, the company posted $2.46 earnings per share. Sell-side analysts predict that AbbVie Inc. will post 14.3 EPS for the current year.

Analyst Upgrades and Downgrades

ABBV has been the subject of a number of recent research reports. Barclays initiated coverage on AbbVie in a research report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price objective for the company. Evercore set a $235.00 price objective on AbbVie in a research report on Friday, May 15th. Morgan Stanley lifted their target price on shares of AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. William Blair restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Finally, DZ Bank upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $253.43.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s migraine drug was cleared for use in migraine attacks on the NHS, a sign of broader adoption potential that could support future sales growth. AbbVie’s migraine drug cleared for migraine attacks on NHS
• Positive Sentiment: Allergan Aesthetics, an AbbVie company, highlighted new consumer research in its aesthetics business, reinforcing ongoing brand visibility and interest in its aesthetics portfolio. Allergan Aesthetics Releases ‘The Aesthetics Evolution: What Consumers Really Want’
• Neutral Sentiment: AbbVie presented at Goldman Sachs’ healthcare conference, which typically provides investors with updates on strategy and pipeline but did not include a major new catalyst in the headline. AbbVie Inc. (ABBV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: AbbVie was mentioned in “final trades” and “below fair value”/discount-stock roundups, which may keep valuation-focused investors interested but are not company-specific operational news. Final trades: AbbVie, Morgan Stanley, Shake Shack and the CBOE
• Negative Sentiment: AbbVie received a Complete Response Letter from the FDA for TrenibotE, its fast-acting neurotoxin candidate. The agency cited manufacturing-related issues and raised no safety or efficacy concerns, but the delay still pushes back a potential new product launch. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE
• Negative Sentiment: AbbVie also terminated its deal with I-Mab to develop a cancer drug, removing a potential pipeline opportunity and signaling a setback in its oncology collaboration strategy. AbbVie terminates deal with I-Mab to develop cancer drug

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.